Study population characteristics
| Characteristic . | N = 33* . |
|---|---|
| Age at start of TVTC, y | 11.0 (1-24) |
| Sex | |
| Female | 17 (51.5) |
| Male | 16 (48.5) |
| BM blasts, % | 32 (10-99) |
| Prior HSCT | |
| No | 24 (72.7) |
| Yes | 9 (27.3) |
| Prior anthracycline (cumulative dose, mg/m2) | 342 (60-492) |
| Group A | n = 14 |
| Length of CR1, d | |
| <180 | 1 (7.1) |
| 180-365 | 6 (50) |
| >365 | 7 (42.9) |
| Prior HSCT | 4 (28.6) |
| Group B | n = 19 |
| Prior HSCT | 5 (26.3) |
| Characteristic . | N = 33* . |
|---|---|
| Age at start of TVTC, y | 11.0 (1-24) |
| Sex | |
| Female | 17 (51.5) |
| Male | 16 (48.5) |
| BM blasts, % | 32 (10-99) |
| Prior HSCT | |
| No | 24 (72.7) |
| Yes | 9 (27.3) |
| Prior anthracycline (cumulative dose, mg/m2) | 342 (60-492) |
| Group A | n = 14 |
| Length of CR1, d | |
| <180 | 1 (7.1) |
| 180-365 | 6 (50) |
| >365 | 7 (42.9) |
| Prior HSCT | 4 (28.6) |
| Group B | n = 19 |
| Prior HSCT | 5 (26.3) |
Group A = first relapse; Group B = second or greater R/R/primary refractory.
Statistics presented as median (minimum-maximum) or n (%).